

1 Appendix D: Evidence tables – RQ S: Risk factors for drug resistance

Table 1: Conaty, 2004

Bibliographic reference	Conaty SJ, Hayward AC, Story A, Glynn JR, Drobniewski FA and Watson JM (2004) Explaining risk factors for drug-resistant tuberculosis in England and Wales: contribution of primary and secondary drug resistance. <i>Epidemiology and Infection</i> 132(6): 1099-108
Study type	Unmatched case-control
Study quality	<p>Sample sufficiently represents the population of interest with regard to key characteristics? <i>yes</i></p> <p>Loss to follow-up sufficiently unrelated to key characteristics? <i>yes</i></p> <p>Prognostic factor of interest adequately measured? <i>yes, although blinding not reported</i></p> <p>Outcome of interest adequately measured? <i>yes, although blinding not reported</i></p> <p>Important potential confounders appropriately accounted for? <i>multivariate analysis used, although effect estimates only adjusted for age and two periods of analysis (1993–1994 and 1998–2000)</i></p> <p>Statistical analysis appropriate? <i>not all factors that underwent univariate analysis were entered into the multivariate analyses; unclear how factors were selected for the multivariate analyses</i></p>
Number of patients	<p>n = 9541</p> <ul style="list-style-type: none"> • isoniazid-resistant tuberculosis = 701 <ul style="list-style-type: none"> – previous history of disease = 63 – no history of disease = 638 • multidrug-resistant tuberculosis = 140 <ul style="list-style-type: none"> – previous history of disease = 54 – no history of disease = 86 • fully sensitive tuberculosis = 8700 <ul style="list-style-type: none"> – previous history of disease = 576 – no history of disease = 8124
Patient characteristics	<p><i>Study group(s)</i></p> <p>All patients in England and Wales with isoniazid- and multidrug-resistant tuberculosis in two time-periods (linked laboratory and surveillance data from 1993–1994 and 1998–2000)^{1,2}</p> <p>Isoniazid resistance was defined as resistance to isoniazid without resistance to rifampicin, pyrazinamide or ethambutol</p> <p>Multidrug resistance was defined as resistance to at least isoniazid and rifampicin</p> <p><i>Comparator</i></p> <p>All patients in England and Wales with fully sensitive tuberculosis in two time-periods (linked laboratory and surveillance data from 1993–1994 and 1998–2000)^{1,2}</p> <p>Fully sensitive tuberculosis was defined as sensitivity to isoniazid, rifampicin, pyrazinamide and ethambutol</p>

Bibliographic reference	Conaty SJ, Hayward AC, Story A, Glynn JR, Drobniewski FA and Watson JM (2004) Explaining risk factors for drug-resistant tuberculosis in England and Wales: contribution of primary and secondary drug resistance. <i>Epidemiology and Infection</i> 132(6): 1099-108		
	<i>Drug susceptibility testing</i> Resistance ratio method on Lowenstein-Jensen media or modified proportion method on liquid media (BACTEC 460)		
	<i>Exclusion</i> Other resistance patterns, such as isolated rifampicin resistance		
	<i>Population characteristics</i> Patients with no history of disease		
		<i>Isoniazid-resistant</i>	<i>Multidrug-resistant</i>
			<i>Fully sensitive</i>
	Age group, n(%)		
	0-19 years	44(10)	5(9)
	20-39 years	244(57)	36(64)
	40-59 years	99(23)	7(13)
	60-79 years	29(7)	7(13)
	≥80 years	10(2)	1(2)
	Sex, n(%)		
	Male	368(58)	52(60)
	Female	268(42)	34(40)
	Site, n(%)		
	Pulmonary	376(62)	55(66)
	Extrapulmonary	231(38)	28(34)
	HIV status, n(%)		
	Positive	39(6)	10(12)
	Negative ³	599(94)	76(88)
	London, n(%)		
	Resident	336(53)	54(64)
	Non-resident	296(47)	31(36)
	Smear status, n(%)		

Bibliographic reference	Conaty SJ, Hayward AC, Story A, Glynn JR, Drobniowski FA and Watson JM (2004) Explaining risk factors for drug-resistant tuberculosis in England and Wales: contribution of primary and secondary drug resistance. <i>Epidemiology and Infection</i> 132(6): 1099-108			
	Positive	209(33)	33(38)	2730(34)
	Negative ⁴	429(67)	53(62)	5394(66)
	Ethnic group, n(%)			
	White	133(22)	25(31)	2673(34)
	Indian subcontinent	239(40)	30(38)	2966(38)
	African	156(27)	22(28)	1492(19)
	Other	67(11)	3(4)	634(8)
	Origin, n(%)			
	Non-UK born	393(72)	59(80)	4411(62)
	UK born	155(28)	15(20)	2742(38)
	Years in the UK, n(%)			
	Born in the UK	155(28)	15(20)	2742(38)
	0-1 years	70(13)	14(19)	715(10)
	2-4 years	74(14)	6(8)	763(10)
	5-9 years	57(10)	7(9)	605(8)
	10-19 years	35(6)	3(4)	488(7)
	20-99 years	42(7)	2(3)	809(11)
	Unknown	115(21)	27(36)	1031(14)
	Patients with a history of disease			
		<i>Isoniazid-resistant</i>	<i>Multidrug-resistant</i>	<i>Fully sensitive</i>
	Age group, n(%)			
	0-19 years	0(0)	2(7)	37(7)
	20-39 years	12(44)	16(57)	181(33)
	40-59 years	5(19)	6(21)	129(24)
	60-79 years	9(33)	4(14)	161(29)
	≥80 years	1(4)	0(0)	39(7)
	Sex, n(%)			
	Male	32(51)	39(72)	323(56)

Bibliographic reference	Conaty SJ, Hayward AC, Story A, Glynn JR, Drobniewski FA and Watson JM (2004) Explaining risk factors for drug-resistant tuberculosis in England and Wales: contribution of primary and secondary drug resistance. <i>Epidemiology and Infection</i> 132(6): 1099-108			
	Female	31(49)	15(28)	253(44)
	Site, n(%)			
	Pulmonary	37(62)	43(83)	444(77)
	Extrapulmonary	23(38)	9(17)	29(23)
	HIV status, n(%)			
	Positive	3(5)	4(7)	15(3)
	Negative ³	60(95)	50(93)	561(97)
	London, n(%)			
	Resident	33(52)	24(46)	191(33)
	Non-resident	30(48)	28(54)	385(67)
	Smear status, n(%)			
	Positive	27(43)	35(65)	249(43)
	Negative ⁴	36(57)	19(35)	327(57)
	Ethnic group, n(%)			
	White	21(33)	13(25)	248(44)
	Indian subcontinent	24(38)	24(45)	215(38)
	African	11(17)	10(19)	71(12)
	Other	6(10)	6(11)	36(6)
	Origin, n(%)			
	Non-UK born	37(64)	39(76)	279(51)
	UK born	21(36)	12(24)	266(49)
	Years in the UK, n(%)			
	Born in the UK	21(36)	12(24)	266(49)
	0-1 years	5(9)	12(24)	46(8)
	2-4 years	7(12)	7(14)	24(5)
	5-9 years	5(9)	4(8)	33(6)
	10-19 years	5(9)	3(6)	30(6)
	20-99 years	1(2)	3(6)	71(13)
	Unknown	14(24)	10(20)	75(14)

Bibliographic reference	Conaty SJ, Hayward AC, Story A, Glynn JR, Drobniewski FA and Watson JM (2004) Explaining risk factors for drug-resistant tuberculosis in England and Wales: contribution of primary and secondary drug resistance. <i>Epidemiology and Infection</i> 132(6): 1099-108																																																								
Location	England and Wales																																																								
Approach to analysis	<p>Risk factors for multidrug-resistant tuberculosis and isolated isoniazid resistance were first examined in a univariate analysis (controlling for the stratum matching for age for 1993–1994)</p> <p>Risk factors were then examined by multiple logistic regression to control for other confounding variables</p> <p>In both univariate and multivariate analysis comparisons were between isolated isoniazid resistance and fully sensitive tuberculosis, and between multidrug-resistant tuberculosis and fully sensitive tuberculosis</p> <p>Individuals with other resistance patterns were excluded from analysis</p> <p>Final multivariate models were selected by backward elimination of variables from full models</p> <p>All odds ratios adjusted for age and two periods of analysis (1993–1994 and 1998–2000)</p>																																																								
Outcomes measures and effect size	<p><i>Risk factors for isoniazid resistance in patients with a history of tuberculosis</i></p> <table border="1"> <thead> <tr> <th><i>Risk factor</i></th> <th><i>Adjusted OR (95% CI)</i></th> <th><i>P-value</i></th> </tr> </thead> <tbody> <tr> <td>HIV-positive³</td> <td>0.6 (0.1 to 4.6)</td> <td>0.59</td> </tr> <tr> <td>London residence</td> <td>1.8 (0.9 to 3.7)</td> <td>0.11</td> </tr> <tr> <td>Smear-positive⁴</td> <td>3.2 (1.1 to 9.2)</td> <td>0.03</td> </tr> <tr> <td>Length of time in the UK</td> <td></td> <td></td> </tr> <tr> <td> Born in the UK</td> <td>1.0 (reference)</td> <td></td> </tr> <tr> <td> In the UK <5 years</td> <td>2.8 (0.8 to 9.7)</td> <td>0.13</td> </tr> <tr> <td> In the UK 5-9 years</td> <td>5.3 (1.2 to 23.5)</td> <td>0.03</td> </tr> <tr> <td> In the UK ≥10 years</td> <td>0.9 (0.3 to 3.8)</td> <td>0.91</td> </tr> <tr> <td>Ethnic group</td> <td></td> <td></td> </tr> <tr> <td> White</td> <td>1.0 (reference)</td> <td></td> </tr> <tr> <td> Indian subcontinent</td> <td>1.2 (0.4 to 3.7)</td> <td>0.72</td> </tr> <tr> <td> Black African</td> <td>0.9 (0.2 to 3.8)</td> <td>0.94</td> </tr> <tr> <td> Other</td> <td>0.5 (0.1 to 2.6)</td> <td>0.42</td> </tr> </tbody> </table> <p><i>Risk factors for isoniazid resistance in patients with no history of tuberculosis</i></p> <table border="1"> <thead> <tr> <th><i>Risk factor</i></th> <th><i>Adjusted OR (95% CI)</i></th> <th><i>P-value</i></th> </tr> </thead> <tbody> <tr> <td>HIV-positive³</td> <td>1.3 (0.8 to 1.9)</td> <td>0.25</td> </tr> <tr> <td>London residence</td> <td>1.4 (1.1 to 1.7)</td> <td>0.001</td> </tr> <tr> <td>Smear-positive⁴</td> <td>1.1 (0.8 to 1.4)</td> <td>0.55</td> </tr> </tbody> </table>			<i>Risk factor</i>	<i>Adjusted OR (95% CI)</i>	<i>P-value</i>	HIV-positive ³	0.6 (0.1 to 4.6)	0.59	London residence	1.8 (0.9 to 3.7)	0.11	Smear-positive ⁴	3.2 (1.1 to 9.2)	0.03	Length of time in the UK			Born in the UK	1.0 (reference)		In the UK <5 years	2.8 (0.8 to 9.7)	0.13	In the UK 5-9 years	5.3 (1.2 to 23.5)	0.03	In the UK ≥10 years	0.9 (0.3 to 3.8)	0.91	Ethnic group			White	1.0 (reference)		Indian subcontinent	1.2 (0.4 to 3.7)	0.72	Black African	0.9 (0.2 to 3.8)	0.94	Other	0.5 (0.1 to 2.6)	0.42	<i>Risk factor</i>	<i>Adjusted OR (95% CI)</i>	<i>P-value</i>	HIV-positive ³	1.3 (0.8 to 1.9)	0.25	London residence	1.4 (1.1 to 1.7)	0.001	Smear-positive ⁴	1.1 (0.8 to 1.4)	0.55
<i>Risk factor</i>	<i>Adjusted OR (95% CI)</i>	<i>P-value</i>																																																							
HIV-positive ³	0.6 (0.1 to 4.6)	0.59																																																							
London residence	1.8 (0.9 to 3.7)	0.11																																																							
Smear-positive ⁴	3.2 (1.1 to 9.2)	0.03																																																							
Length of time in the UK																																																									
Born in the UK	1.0 (reference)																																																								
In the UK <5 years	2.8 (0.8 to 9.7)	0.13																																																							
In the UK 5-9 years	5.3 (1.2 to 23.5)	0.03																																																							
In the UK ≥10 years	0.9 (0.3 to 3.8)	0.91																																																							
Ethnic group																																																									
White	1.0 (reference)																																																								
Indian subcontinent	1.2 (0.4 to 3.7)	0.72																																																							
Black African	0.9 (0.2 to 3.8)	0.94																																																							
Other	0.5 (0.1 to 2.6)	0.42																																																							
<i>Risk factor</i>	<i>Adjusted OR (95% CI)</i>	<i>P-value</i>																																																							
HIV-positive ³	1.3 (0.8 to 1.9)	0.25																																																							
London residence	1.4 (1.1 to 1.7)	0.001																																																							
Smear-positive ⁴	1.1 (0.8 to 1.4)	0.55																																																							

Bibliographic reference	Conaty SJ, Hayward AC, Story A, Glynn JR, Drobniowski FA and Watson JM (2004) Explaining risk factors for drug-resistant tuberculosis in England and Wales: contribution of primary and secondary drug resistance. <i>Epidemiology and Infection</i> 132(6): 1099-108		
	Length of time in the UK		
	Born in the UK	1.0 (reference)	
	In the UK <5 years	1.1 (0.8 to 1.5)	0.65
	In the UK 5-9 years	1.2 (0.8 to 1.7)	0.34
	In the UK ≥10 years	0.9 (0.7 to 1.3)	0.70
	Ethnic group		
	White	1.0 (reference)	
	Indian subcontinent	1.6 (1.2 to 2.1)	0.003
	Black African	1.7 (1.2 to 2.4)	0.002
	Other	1.9 (1.3 to 2.8)	0.001
	<i>Risk factors for multidrug resistance in patients with a history of tuberculosis</i>		
	<i>Risk factor</i>	<i>Adjusted OR (95% CI)</i>	<i>P-value</i>
	HIV-positive ³	2.8 (0.6 to 11.9)	0.17
	London residence	1.2 (0.6 to 2.4)	0.67
	Smear-positive ⁴	5.9 (1.8 to 19.0)	0.003
	Length of time in the UK		
	Born in the UK	1.0 (reference)	
	In the UK <5 years	5.8 (1.8 to 18.5)	0.003
	In the UK 5-9 years	2.2 (0.4 to 11.6)	0.34
	In the UK ≥10 years	1.7 (0.4 to 6.9)	0.46
	Ethnic group		
	White	1.0 (reference)	
	Indian subcontinent	1.5 (0.5 to 5.1)	0.48
	Black African	1.1 (0.3 to 4.6)	0.91
	Other	1.5 (0.3 to 6.8)	0.56
	<i>Risk factors for multidrug resistance in patients with no history of tuberculosis</i>		
	<i>Risk factor</i>	<i>Adjusted OR (95% CI)</i>	<i>P-value</i>
	HIV-positive ³	2.5 (1.2 to 5.2)	0.02

Bibliographic reference	Conaty SJ, Hayward AC, Story A, Glynn JR, Drobniowski FA and Watson JM (2004) Explaining risk factors for drug-resistant tuberculosis in England and Wales: contribution of primary and secondary drug resistance. <i>Epidemiology and Infection</i> 132(6): 1099-108		
	London residence	2.0 (1.2 to 3.3)	0.006
	Smear-positive ⁴	1.4 (0.7 to 2.5)	0.32
	Length of time in the UK		
	Born in the UK	1.0 (reference)	
	In the UK <5 years	3.2 (1.4 to 7.4)	0.006
	In the UK 5-9 years	3.0 (1.1 to 8.5)	0.04
	In the UK ≥10 years	1.2 (0.4 to 3.7)	0.76
	Ethnic group		
	White	1.0 (reference)	
	Indian subcontinent	0.8 (0.4 to 1.5)	0.41
	Black African	0.6 (0.3 to 1.2)	0.16
	Other	0.3 (0.1 to 0.9)	0.04
Source of funding	1 author supported by the United Kingdom's Department for International Development and the Department of Health; 1 author supported by Camden Primary Care Trust		
Comments	<p>¹ Reason provided for 2 time periods: to maximise power and investigate any differences in risk factors over time</p> <p>² Drug sensitivity results obtained from MycobNet, the UK Mycobacterial Surveillance Network; linked risk factor information obtained from the National Tuberculosis Survey and the Enhanced Tuberculosis Surveillance data</p> <p>³ At analysis subjects with no recorded HIV status were classified as HIV negative</p> <p>⁴ At analysis subjects with no smear result recorded were assumed to be smear negative</p> <p>⁵ At analysis subjects with no recorded history of tuberculosis were classified as 'no previous tuberculosis'</p> <p>Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; OR, odds ratio</p>		

Table 2: French, 2008

Bibliographic reference	French CE, Glynn JR, Kruijshaar ME, Ditah IC, Delpech V and Abubakar I (2008) The association between HIV and antituberculosis drug resistance. <i>European Respiratory Journal</i> 32(3): 718-25
Study type	Unmatched case-control

Bibliographic reference	French CE, Glynn JR, Kruijshaar ME, Ditah IC, Delpech V and Abubakar I (2008) The association between HIV and antituberculosis drug resistance. <i>European Respiratory Journal</i> 32(3): 718-25														
Study quality	<p>Sample sufficiently represents the population of interest with regard to key characteristics? <i>yes</i></p> <p>Loss to follow-up sufficiently unrelated to key characteristics? <i>yes</i></p> <p>Prognostic factor of interest adequately measured? <i>yes, although blinding not reported</i></p> <p>Outcome of interest adequately measured? <i>yes, although blinding not reported</i></p> <p>Important potential confounders appropriately accounted for? <i>cases and controls unmatched; multivariate analysis used, although it was unclear which confounders were accounted for</i></p> <p>Statistical analysis appropriate? <i>a number of factors reported in the univariate analyses were not reported as multivariate analyses</i></p>														
Number of patients	<p>n = 18130</p> <ul style="list-style-type: none"> • isoniazid-resistant tuberculosis = 1195 • multidrug-resistant tuberculosis = 125 • fully sensitive tuberculosis = 16810 														
Patient characteristics	<p><i>Study group(s)</i> All new cases of isoniazid- and multidrug-resistant tuberculosis in England and Wales between 1999 and 2005¹</p> <p><i>Comparator</i> All new cases of fully sensitive tuberculosis in England and Wales between 1999 and 2005¹</p> <p><i>Drug susceptibility testing</i> Isolates are tested for resistance to the four firstline drugs (isoniazid, rifampicin, ethambutol and pyrazinamide), and some second-line drugs Reference laboratories used the resistance ratio or the proportion method, and are subject to quality assurance systems</p> <p><i>Exclusion</i> Cases with <i>M. bovis</i> were excluded from calculations of pyrazinamide resistance since they are usually intrinsically resistant to it</p> <p><i>Population characteristics</i></p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th></th> <th style="text-align: center;"><i>Isoniazid-resistant</i></th> <th style="text-align: center;"><i>Multidrug-resistant</i></th> <th style="text-align: center;"><i>Fully sensitive</i></th> </tr> </thead> <tbody> <tr> <td>HIV status², n</td> <td></td> <td></td> <td></td> </tr> <tr> <td style="padding-left: 20px;">Negative</td> <td style="text-align: center;">1108</td> <td style="text-align: center;">111</td> <td style="text-align: center;">15755</td> </tr> </tbody> </table>				<i>Isoniazid-resistant</i>	<i>Multidrug-resistant</i>	<i>Fully sensitive</i>	HIV status ² , n				Negative	1108	111	15755
	<i>Isoniazid-resistant</i>	<i>Multidrug-resistant</i>	<i>Fully sensitive</i>												
HIV status ² , n															
Negative	1108	111	15755												

Bibliographic reference	French CE, Glynn JR, Kruijshaar ME, Ditah IC, Delpech V and Abubakar I (2008) The association between HIV and antituberculosis drug resistance. European Respiratory Journal 32(3): 718-25			
	Positive	87	14	1055
	Age, n			
	15-44 years	957	108	11017
	45-64 years	177	12	3235
	≥65 years	61	5	2558
	Sex, n			
	Male	704	66	9488
	Female	490	59	7296
	Missing data	1 (0.1%)	0 (0.0%)	26 (0.2%)
	Place of reporting, n			
	Outside London	534	58	9914
	London	661	67	6896
	Ethnic group, n			
	White	193	13	4438
	Black Caribbean	91	3	474
	Black African	324	51	3736
	Indian/Pakistani/Bangladeshi	400	39	6133
	Other	168	16	1825
	Missing data	19 (1.3%)	3 (2.4%)	204 (1.2%)
	Place of birth and time since entry into the UK, n			
	UK born	275	19	4705
	Non-UK born (<2 years)	182	37	2250
	Non-UK born (≥2 years)	562	53	7359
	Non-UK born (unknown)	116	11	1654
	Missing data	60 (5.0%)	5 (4.0%)	842 (5.0%)
	Site, n			
	Extrapulmonary	427	35	5708
	Smear-positive pulmonary	415	46	5826
	Other pulmonary	350	44	5234

Bibliographic reference	French CE, Glynn JR, Kruijshaar ME, Ditah IC, Delpech V and Abubakar I (2008) The association between HIV and antituberculosis drug resistance. <i>European Respiratory Journal</i> 32(3): 718-25			
	Missing data	3 (0.3%)	0 (0.0%)	42 (0.2%)
Location	England and Wales			
Approach to analysis	Multivariate models were built using a forward-fitting approach, and interactions were assessed using the likelihood ratio test In both univariate and multivariate analysis comparisons were between isolated isoniazid resistance and fully sensitive tuberculosis, and between multidrug-resistant tuberculosis and fully sensitive tuberculosis			
Outcomes measures and effect size	<i>Risk factors for isoniazid resistance in patients with no history of tuberculosis</i>			
	<i>Risk factor</i>	<i>Adjusted OR (95% CI)</i>		<i>P-value</i>
	HIV status ²			
	Negative	1.0 (reference)		0.895
	Positive	1.02 (0.80 to 1.30)		
	Age			
	15-44 years	1.0 (reference)		<0.001
	45-64 years	0.70 (0.59 to 0.83)		
	≥65 years	0.34 (0.26 to 0.44)		
	Place of reporting			
	Outside London	1.0 (reference)		<0.001
	London	1.52 (1.34 to 1.72)		
	Ethnic group			
	White	1.0 (reference)		<0.001
Black Caribbean	3.11 (2.36 to 4.08)			
Black African	1.22 (1.00 to 1.50)			
Indian/Pakistani/Bangladeshi	1.18 (0.99 to 1.42)			
Other	1.40 (1.12 to 1.76)			
	<i>Risk factors for multidrug resistance in patients with no history of tuberculosis</i>			
<i>Risk factor</i>	<i>Adjusted OR (95% CI)</i>		<i>P-value</i>	
HIV status ²				
Negative	1.0 (reference)		0.775	
Positive	0.91 (0.47 to 1.76)			
Age				

Bibliographic reference		French CE, Glynn JR, Kruijshaar ME, Ditah IC, Delpech V and Abubakar I (2008) The association between HIV and antituberculosis drug resistance. European Respiratory Journal 32(3): 718-25	
	15-44 years	1.0 (reference)	0.010
	45-64 years	0.52 (0.27 to 0.99)	
	≥65 years	0.35 (0.14 to 0.90)	
	Ethnic group		0.323
	White	1.0 (reference)	
	Black Caribbean	1.40 (0.39 to 5.01)	
	Black African	2.02 (0.88 to 4.64)	
	Indian/Pakistani/Bangladeshi	1.33 (0.61 to 2.90)	
	Other	1.39 (0.56 to 3.45)	
	Place of birth and time since entry into the UK		0.028
	UK born	1.0 (reference)	
	Non-UK born (<2 years)	2.23 (1.08 to 4.63)	
	Non-UK born (≥2 years)	1.19 (0.59 to 2.38)	
	Non-UK born (unknown)	1.24 (0.53 to 2.91)	
Source of funding	No details provided		
Comments			
<p>¹ Drug sensitivity results obtained from MycobNet, the UK Mycobacterial Surveillance Network; linked risk factor information obtained from Enhanced Tuberculosis Surveillance data</p> <p>² The Enhanced Tuberculosis Surveillance system does not collect information on HIV status, so this information was obtained by matching case reports (for 1999–2005) with the national HIV/AIDS reports database (for 1979–2006) using in-house matching software; matching was not carried out on cases aged <15 years as HIV in children is reported separately; tuberculosis cases that were not matched to HIV/ AIDS reports were considered to be HIV-negative (although it is recognised that they are more accurately described as ‘not known to be HIV-positive’); cases that were diagnosed with HIV >1 year after the date of tuberculosis diagnosis were excluded, since it was unknown whether they were infected with HIV at the time of tuberculosis diagnosis</p> <p>Abbreviations: AIDS, autoimmune deficiency syndrome; HIV, human immunodeficiency virus</p>			

Table 3: Kruijshaar, 2008

Bibliographic reference	Kruijshaar ME, Watson JM, Drobniowski F, Anderson C, Brown TJ, Magee JG, Smith EG, Story A and Abubakar I (2008) Increasing antituberculosis drug resistance in the United Kingdom: analysis of National Surveillance Data. BMJ 336(7655): 1231-4
--------------------------------	--

Bibliographic reference	Kruijshaar ME, Watson JM, Drobniewski F, Anderson C, Brown TJ, Magee JG, Smith EG, Story A and Abubakar I (2008) Increasing antituberculosis drug resistance in the United Kingdom: analysis of National Surveillance Data. BMJ 336(7655): 1231-4								
Study type	Observational								
Study quality	<p>Sample sufficiently represents the population of interest with regard to key characteristics?</p> <p>Loss to follow-up sufficiently unrelated to key characteristics? <i>unclear; loss to follow-up, its reasons and the characteristics of those lost not reported</i></p> <p>Prognostic factor of interest adequately measured? <i>yes, although blinding not reported</i></p> <p>Outcome of interest adequately measured? <i>Approach to drug susceptibility testing not reported; blinding not reported</i></p> <p>Important potential confounders appropriately accounted for? <i>yes</i></p> <p>Statistical analysis appropriate? <i>yes</i></p>								
Number of patients	n = 28485								
Patient characteristics	<p><i>Study group(s)</i></p> <p>All cases of isoniazid-, rifampicin- and multidrug-resistant tuberculosis in England, Wales and Northern Ireland between 1998 and 2005¹</p> <p>Multidrug resistant tuberculosis is defined as resistance to at least isoniazid and rifampicin</p> <p><i>Comparator</i></p> <p>All cases of fully sensitive tuberculosis in England, Wales and Northern Ireland between 1998 and 2005¹</p> <p><i>Tuberculosis diagnosis</i></p> <p>Tuberculosis cases were either confirmed by culture to be caused by M tuberculosis complex or met the following criteria: a clinician's judgment that the patient's clinical or radiological signs are compatible with tuberculosis and clinician's decision to treat the patient with a full course of antituberculosis treatment</p> <p><i>Exclusion</i></p> <p>Most <i>M. bovis</i> isolates are resistant to pyrazinamide and were therefore excluded these from analyses of pyrazinamide resistance</p> <p><i>Population characteristics</i></p> <table border="1"> <thead> <tr> <th></th> <th><i>Culture confirmed cases (tested for isoniazid and rifampicin)</i></th> </tr> </thead> <tbody> <tr> <td>All cases</td> <td>28 485</td> </tr> <tr> <td>Median (IQR) age (years)</td> <td>35 (26-54)</td> </tr> <tr> <td>Male</td> <td>16 164 (56.8)</td> </tr> </tbody> </table>		<i>Culture confirmed cases (tested for isoniazid and rifampicin)</i>	All cases	28 485	Median (IQR) age (years)	35 (26-54)	Male	16 164 (56.8)
	<i>Culture confirmed cases (tested for isoniazid and rifampicin)</i>								
All cases	28 485								
Median (IQR) age (years)	35 (26-54)								
Male	16 164 (56.8)								

Bibliographic reference	Kruijshaar ME, Watson JM, Drobniewski F, Anderson C, Brown TJ, Magee JG, Smith EG, Story A and Abubakar I (2008) Increasing antituberculosis drug resistance in the United Kingdom: analysis of National Surveillance Data. <i>BMJ</i> 336(7655): 1231-4			
	Born in UK			8035 (31.4)
	Median (IQR) time since entry to UK (years)			4 (2-13)
	Ethnic group:			
	White			7541 (27.7)
	Black Caribbean			770 (2.8)
	Black African			5967 (21.9)
	Black other			241 (0.9)
	Indian, Pakistani, Bangladeshi			9963 (36.6)
	Chinese			448 (1.6)
	Other			2327 (8.5)
	Reported in London			11 851 (41.6)
	Pulmonary disease			18 997 (67.0)
	Previous diagnosis			1889 (8.3)
	<i>M. tuberculosis</i>			27884 (99.4)
	<i>M. bovis</i>			123 (0.4)
	<i>M. africanum</i>			33 (0.1)
	Sputum smear positive			9909 (60.6)
Location	England, Wales, and Northern Ireland			
Approach to analysis	Multivariable models adjusted for age, sex, place of birth (born in the UK or elsewhere), ethnic group (white, black Caribbean, black African, black other, Indian/Pakistani/Bangladeshi, Chinese, other including mixed), region (London versus outside London), previous diagnosis, and site of disease (pulmonary z)			
Outcomes measures and effect size	<i>Risk factors for isoniazid resistance in patients with tuberculosis living in London</i>			
	<i>Risk factor</i>	<i>n</i>	<i>% resistant</i>	<i>Adjusted OR (95% CI)</i>
	Age (linear)	11 848	8.5	0.99 (0.98 to 0.99)
	Sex:			
	Female	5056	8.1	0.92 (0.79 to 1.08)
Male	6783	8.8	Reference	

Bibliographic reference	Kruijshaar ME, Watson JM, Drobniewski F, Anderson C, Brown TJ, Magee JG, Smith EG, Story A and Abubakar I (2008) Increasing antituberculosis drug resistance in the United Kingdom: analysis of National Surveillance Data. <i>BMJ</i> 336(7655): 1231-4			
Born in UK:				
No	8822	7.9	0.76 (0.60 to 0.95)	
Yes	1806	11.1	Reference	
Ethnic group:				
White	1747	7.7	Reference	
Black Caribbean	470	21.5	2.93 (2.11 to 4.09)	
Black African	3877	8.7	1.08 (0.80 to 1.45)	
Black other	174	10.9	1.38 (0.75 to 2.55)	
Indian, Pakistani, Bangladeshi	3606	6.8	0.89 (0.66 to 1.19)	
Chinese	174	9.8	1.41 (0.75 to 2.64)	
Other	1464	8.4	1.04 (0.74 to 1.46)	
Year (linear)	11 851	8.5	1.04 (1.00 to 1.07)	
Previous diagnosis:				
Yes	655	10.2	1.35 (1.02 to 1.78)	
No	8504	8.5	Reference	
Site of disease:				
Pulmonary	7556	9	1.06 (0.89 to 1.25)	
Extrapulmonary	4247	7.7	Reference	
<i>Risk factors for isoniazid resistance in patients with tuberculosis living outside of London</i>				
<i>Risk factor</i>	<i>n</i>	<i>% resistant</i>	<i>Adjusted OR (95% CI)</i>	
Age (linear)	16 633	3.0	0.98 (0.98 to 0.99)	
Sex:				
Female	7227	2.9	0.81 (0.69 to 0.96)	
Male	9381	3.1	Reference	
Born in UK:				

Bibliographic reference	Kruijshaar ME, Watson JM, Drobniewski F, Anderson C, Brown TJ, Magee JG, Smith EG, Story A and Abubakar I (2008) Increasing antituberculosis drug resistance in the United Kingdom: analysis of National Surveillance Data. <i>BMJ</i> 336(7655): 1231-4			
	No	8700	3.2	1.49 (1.16 to 1.92)
	Yes	6229	2.7	Reference
	Ethnic group:			
	White	5794	2.3	Reference
	Black Caribbean	300	2.1	1.35 (0.77 to 2.36)
	Black African	2090	2.1	0.99 (0.68 to 1.43)
	Black other	67	1.2	0.99 (0.30 to 3.28)
	Indian, Pakistani, Bangladeshi	6357	4.0	1.26 (0.94 to 1.69)
	Chinese	274	5.1	1.71 (0.99 to 2.95)
	Other	863	3.2	1.65 (1.11 to 2.44)
	Year (linear)	16 634	3.0	1.01 (0.98 to 1.05)
	Previous diagnosis:			
	Yes	1234	3.2	1.80 (1.40 to 2.32)
	No	12 278	0.7	Reference
	Site of disease:			
	Pulmonary	11 441	2.8	0.82 (0.69 to 0.98)
	Extrapulmonary	5097	3.4	Reference
	<i>Risk factors for rifampicin resistance in patients with tuberculosis</i>			
	<i>Risk factor</i>	<i>n</i>	<i>% resistant</i>	<i>Adjusted OR (95% CI)</i>
	Age (linear)	28481	1.2	0.98 (0.97 to 0.99)
	Sex:			
	Female	12283	1.2	0.83 (0.64 to 1.08)
	Male	16164	1.3	Reference
	Born in UK:			
	No	17522	1.4	1.88 (1.24 to 2.86)

Bibliographic reference	Kruijshaar ME, Watson JM, Drobniewski F, Anderson C, Brown TJ, Magee JG, Smith EG, Story A and Abubakar I (2008) Increasing antituberculosis drug resistance in the United Kingdom: analysis of National Surveillance Data. <i>BMJ</i> 336(7655): 1231-4			
Yes	8035	0.7	Reference	
Ethnic group:				
White	7541	0.7	Reference	
Black Caribbean	770	9.1	1.28 (0.59 to 2.79)	
Black African	5967	1.7	0.98 (0.59 to 1.64)	
Black other	241	2.5	1.87 (0.69 to 5.06)	
Indian, Pakistani, Bangladeshi	9963	1.2	0.94 (0.59 to 1.50)	
Chinese	448	1.3	0.83 (0.28 to 2.45)	
Other	2327	1.7	0.97 (0.54 to 1.75)	
Year (linear)	28485	1.2	1.03 (0.98 to 1.09)	
Region of reporting:				
London	11851	1.5	0.81 (0.62 to 1.05)	
Outside London	16634	1.0	Reference	
Previous diagnosis:				
Yes	1889	3.5	4.72 (3.50 to 6.35)	
No	20782	1.0	Reference	
Site of disease:				
Pulmonary	18997	1.3	1.48 (1.10 to 1.98)	
Extrapulmonary	9344	1.0	Reference	
<i>Risk factors for multidrug resistance in patients with tuberculosis</i>				
<i>Risk factor</i>	<i>n</i>	<i>% resistant</i>	<i>Adjusted OR (95% CI)</i>	
Age (linear)	28481	0.9	0.98 (0.59 to 1.08)	
Sex:				
Female	12283	0.9	0.80 (0.59 to 1.08)	
Male	16164	0.9	Reference	

Bibliographic reference	Kruijshaar ME, Watson JM, Drobniewski F, Anderson C, Brown TJ, Magee JG, Smith EG, Story A and Abubakar I (2008) Increasing antituberculosis drug resistance in the United Kingdom: analysis of National Surveillance Data. <i>BMJ</i> 336(7655): 1231-4			
	Born in UK:			
	No	17522	1.1	1.62(0.99 to 2.66)
	Yes	8035	0.5	Reference
	Ethnic group:			
	White	7541	0.4	Reference
	Black Caribbean	770	0.5	1.01 (0.30 to 3.43)
	Black African	5967	1.3	1.77 (0.92 to 3.41)
	Black other	241	1.7	2.44 (0.68 to 8.81)
	Indian, Pakistani, Bangladeshi	9963	1	1.63 (0.91 to 2.95)
	Chinese	448	1.1	1.77 (0.56 to 5.54)
	Other	2327	1.2	1.32 (0.62 to 2.84)
	Year (linear)	28485	0.9	1.01 (0.95 to 1.08)
	Region of reporting:			
	London	11851	1.0	1.04 (0.76 to 1.42)
	Outside London	16634	0.8	Reference
	Previous diagnosis:			
	Yes	1889	2.8	5.44 (3.88 to 7.63)
	No	20782	0.7	Reference
	Site of disease:			
	Pulmonary	18997	1.0	1.40 (1.00 to 1.96)
	Extrapulmonary	9344	0.8	Reference
Source of funding	None			
Comments				
¹ Drug sensitivity results obtained from MycobNet, the UK Mycobacterial Surveillance Network; linked risk factor information obtained from Enhanced Tuberculosis Surveillance data				

Bibliographic reference	Kruijshaar ME, Watson JM, Drobniewski F, Anderson C, Brown TJ, Magee JG, Smith EG, Story A and Abubakar I (2008) Increasing antituberculosis drug resistance in the United Kingdom: analysis of National Surveillance Data. <i>BMJ</i> 336(7655): 1231-4
--------------------------------	---

Abbreviations: CI, confidence interval; IQR, interquartile range; OR, odds ratio

Table 4: Maguire, 2011

Bibliographic reference	Maguire H, Brailsford S, Carless J, Yates M, Altass L, Yates S, Anaraki S, Charlett A, Lozewicz S, Lipman M and Bothamley G (2011) Large outbreak of isoniazid-mono-resistant tuberculosis in London, 1995 to 2006: case-control study and recommendations. <i>Euro Surveillance</i> 16(13): pii: 19830
Study type	Unmatched case-control
Study quality	<p>Sample sufficiently represents the population of interest with regard to key characteristics? <i>yes</i></p> <p>Loss to follow-up sufficiently unrelated to key characteristics? <i>yes</i></p> <p>Prognostic factor of interest adequately measured? <i>yes, although blinding not reported; some data collected by questionnaire (i.e. may be some reliance on recall)</i></p> <p>Outcome of interest adequately measured? <i>yes, although blinding not reported; some data collected by questionnaire (i.e. may be some reliance on recall)</i></p> <p>Important potential confounders appropriately accounted for? <i>multivariate analysis used, but unclear which confounders were controlled for; cases and controls unmatched</i></p> <p>Statistical analysis appropriate? <i>yes</i></p>
Number of patients	<p>n = 18040</p> <ul style="list-style-type: none"> • isoniazid-resistant tuberculosis = 293 • fully sensitive tuberculosis = 17747 <p>For the following variables, only controls with a known place of residence were included (n=17,740): sex, age, site of disease, sputum smear status, type of employment, ethnicity and country of birth</p>
Patient characteristics	<p><i>Study group(s)</i></p> <p>All individuals with an isoniazid-mono-resistant <i>M. tuberculosis</i> strain diagnosed from 1995 to the third quarter of 2006 with an indistinguishable RFLP or MIRU-VNTR pattern who was resident in or had an epidemiological link with London</p> <p><i>Comparator</i></p> <p>All other individuals with TB reported during 2000 to 2001 to the HPA London regional epidemiology unit as part of routine surveillance on a paper-based questionnaire and those reported during 2002 to 2005 electronically by clinicians to the HPA London TB Register.</p>

Bibliographic reference	Maguire H, Brailsford S, Carless J, Yates M, Altass L, Yates S, Anaraki S, Charlett A, Lozewicz S, Lipman M and Bothamley G (2011) Large outbreak of isoniazid-mono-resistant tuberculosis in London, 1995 to 2006: case-control study and recommendations. Euro Surveillance 16(13): pii: 19830		
	<i>Population characteristics</i>		
		<i>Cases 2000 to third quarter 2006</i>	<i>Controls 2000–2005</i>
	Sex:		
	Male	206	9753
	Female	86	7959
	Unknown	1	28
	Age:		
	0-14 years	5	1035
	15-24 years	53	3109
	25-34 years	91	5363
	35-44 years	83	3184
	45-64 years	47	3116
	≥65 years	14	1092
	Unknown	0	31
	Ethnicity:		
	Black African	43	5617
	Black Caribbean	85	605
	Black (other)	8	264
	White	99	2434
	Indian subcontinent	15	5691
	Chinese	1	251
	Other	18	2282
	Unknown	24	596
	Country of birth:		
	Abroad	112	12953
	UK	153	2930
	Unknown	28	1857
	Employment:		
	Prisoner	13	26

Bibliographic reference	Maguire H, Brailsford S, Carless J, Yates M, Altass L, Yates S, Anaraki S, Charlett A, Lozewicz S, Lipman M and Bothamley G (2011) Large outbreak of isoniazid-mono-resistant tuberculosis in London, 1995 to 2006: case-control study and recommendations. Euro Surveillance 16(13): pii: 19830		
	Healthcare	9	523
	Unemployed	120	2095
	Asylum seeker/refugee	2	52
	Drug dealer/sex worker	7	3
	Educational setting	18	2269
	Retired	10	759
	Other	114	11997
	Unknown	0	16
	Pulmonary disease:		
	No	40	8531
	Yes	253	9193
	Unknown	0	16
	Sputum smear status:		
	Negative	79	4138
	Positive	153	3266
	Unknown	51	4365
	Not tested	10	5971
Location	London		
Approach to analysis	Logistic regression was used to obtain unadjusted odds ratios for each variable Those variables found to be statistically significant were included in a multivariable analysis using logistic regression to control for confounders		
Outcomes measures and effect size	<i>Risk factors for isoniazid resistance in patients with tuberculosis</i>		
	<i>Risk factor</i>	<i>Adjusted OR (95% CI)</i>	<i>P-value</i>
	Sex:		
	Male	1.34 (0.98 to 1.83)	0.07
	Female	Reference	-
	Age:		
	0-14 years	0.30 (0.09 to 1.01)	0.05
	15-24 years	Reference	-

Bibliographic reference	Maguire H, Brailsford S, Carless J, Yates M, Altass L, Yates S, Anaraki S, Charlett A, Lozewicz S, Lipman M and Bothamley G (2011) Large outbreak of isoniazid-mono-resistant tuberculosis in London, 1995 to 2006: case-control study and recommendations. Euro Surveillance 16(13): pii: 19830		
	25-34 years	0.79 (0.52 to 1.20)	0.27
	35-44 years	0.64 (0.41 to 1.00)	0.05
	45-64 years	0.45 (0.27 to 0.74)	0.002
	≥65 years	0.23 (0.10 to 0.51)	<0.001
	Ethnicity:		
	Black African	Reference	-
	Black Caribbean	12.52 (7.69 to 20.37)	<0.001
	Black (other)	3.29 (1.35 to 8.02)	0.009
	White	2.94 (1.79 to 4.83)	<0.001
	Indian subcontinent	0.57 (0.30 to 1.10)	0.092
	Chinese	0.68 (0.09 to 5.05)	0.703
	Other	1.210 (0.67 to 2.19)	0.528
	Country of birth:		
	Abroad	Reference	-
	UK	2.40 (1.68 to 3.43)	<0.001
	Employment:		
	Prisoner	20.21 (6.75 to 60.56)	<0.001
	Healthcare	1.53 (0.67 to 3.51)	0.316
	Unemployed	4.09 (2.97 to 5.63)	<0.001
	Asylum seeker/refugee	8.09 (1.02 to 64.41)	0.048
	Drug dealer/sex worker	187.07 (28.40 to 1232.35)	<0.001
	Educational setting	1.22 (0.67 to 2.23)	0.524
	Retired	1.69 (0.71 to 4.06)	0.239
	Other	Reference	-
	Pulmonary disease:		
	No	Reference	-
	Yes	1.52 (0.98 to 2.36)	0.61
	Sputum smear status:		
	Negative	Reference	-

Bibliographic reference	Maguire H, Brailsford S, Carless J, Yates M, Altass L, Yates S, Anaraki S, Charlett A, Lozewicz S, Lipman M and Bothamley G (2011) Large outbreak of isoniazid-mono-resistant tuberculosis in London, 1995 to 2006: case-control study and recommendations. Euro Surveill 16(13): pii: 19830		
	Positive	1.37 (0.98 to 1.93)	0.067
Source of funding	No details provided		
Comments			
Abbreviations: CI, confidence interval; HPA, Health Protection Agency; MIRU-VNTR, mycobacterial interspersed repetitive units variable number tandem repeat; OR, odds ratio; RFLP, restriction fragment length polymorphism			

Table 5: Melzer, 2010

Bibliographic reference	Melzer M, Gupta N, Petersen I, Cook S and Hall B (2010) Previous treatment in predicting drug-resistant tuberculosis in an area bordering East London, UK. International Journal of Infectious Diseases 14(8): e717-22
Study type	Observational
Study quality	<p>Sample sufficiently represents the population of interest with regard to key characteristics? <i>yes</i></p> <p>Loss to follow-up sufficiently unrelated to key characteristics? <i>yes</i></p> <p>Prognostic factor of interest adequately measured? <i>yes, although blinding not reported</i></p> <p>Outcome of interest adequately measured? <i>yes, although blinding not reported</i></p> <p>Important potential confounders appropriately accounted for? <i>multivariate analysis used, but unclear which confounders were controlled for</i></p> <p>Statistical analysis appropriate? <i>yes, although analyses not reported for site of disease, which was recorded and reported in population characteristics</i></p>
Number of patients	<p>n = 380</p> <ul style="list-style-type: none"> • drug-resistant tuberculosis = 30 • fully sensitive tuberculosis = 350
Patient characteristics	<p><i>Study group(s)</i></p> <p>All cases of microbiologically confirmed drug resistant tuberculosis at King George, Harold Wood and Oldchurch hospitals in Essex, part of the Barking, Havering and Redbridge Trust between January 2003 to December 2006</p> <p>Drug resistance was defined as MDR, isoniazid, or rifampin resistance. MDR was defined as resistance to at least rifampin and isoniazid</p> <p><i>Comparator</i></p> <p>All cases of microbiologically confirmed drug susceptible tuberculosis at King George, Harold Wood and Oldchurch</p>

Bibliographic reference	<p>Melzer M, Gupta N, Petersen I, Cook S and Hall B (2010) Previous treatment in predicting drug-resistant tuberculosis in an area bordering East London, UK. <i>International Journal of Infectious Diseases</i> 14(8): e717-22</p>
	<p>hospitals in Essex, part of the Barking, Havering and Redbridge Trust between January 2003 to December 2006</p> <p><i>Tuberculosis diagnosis</i> All samples were auramine stained and subcultured onto Lowenstein–Jensen and Middlebrook media All smear-positive and extrapulmonary samples were directly inoculated into Kirschner’s broth and the automated liquid MB/BacT system to expedite the time to culture Speciation was determined by biochemical testing and DNA hybridization (Accuprobe)</p> <p><i>Drug susceptibility testing</i> Antimicrobial susceptibility testing was performed using the resistance ratio method on Lowenstein-Jensen medium or the radiometric BACTEC 460 method</p> <p><i>Exclusion</i> Patients on tuberculosis on treatment without microbiological confirmation or those with smear-positive specimens whose cultures failed to grow, grew mycobacteria other than <i>M. tuberculosis</i>, or were contaminated Patients without drug susceptibility results</p> <p><i>Population characteristics</i></p>

Bibliographic reference	Melzer M, Gupta N, Petersen I, Cook S and Hall B (2010) Previous treatment in predicting drug-resistant tuberculosis in an area bordering East London, UK. <i>International Journal of Infectious Diseases</i> 14(8): e717-22																																																																																												
			<table border="1"> <thead> <tr> <th></th> <th data-bbox="1400 260 1556 323">Drug-resistant^a n = 30 (7.9%)</th> <th data-bbox="1556 260 1776 323">Drug-susceptible n = 350 (92.1%)</th> </tr> </thead> <tbody> <tr> <td colspan="3">Age, years</td> </tr> <tr> <td>0–19</td> <td>4 (13.3%)</td> <td>29 (8.3%)</td> </tr> <tr> <td>20–39</td> <td>18 (60%)</td> <td>198 (56.6%)</td> </tr> <tr> <td>40–59</td> <td>4 (13.3%)</td> <td>67 (19.1%)</td> </tr> <tr> <td>60–79</td> <td>4 (13.3%)</td> <td>38 (10.9%)</td> </tr> <tr> <td>≥80</td> <td>0</td> <td>18 (5.1%)</td> </tr> <tr> <td colspan="3">Sex</td> </tr> <tr> <td>Male</td> <td>17 (56.7%)</td> <td>182 (52%)</td> </tr> <tr> <td>Female</td> <td>13 (43.3%)</td> <td>168 (48%)</td> </tr> <tr> <td colspan="3">Country of origin</td> </tr> <tr> <td>High-incidence (drug resistance)</td> <td>14 (46.7%)</td> <td>185 (52.9%)</td> </tr> <tr> <td>Low-incidence (drug resistance)</td> <td>16 (53.3%)</td> <td>165 (47.1%)</td> </tr> <tr> <td colspan="3">Date of arrival in the UK</td> </tr> <tr> <td><2000</td> <td>9 (30%)</td> <td>102 (29.1%)</td> </tr> <tr> <td>≥2000</td> <td>11 (36.7%)</td> <td>127 (36.3%)</td> </tr> <tr> <td>Missing or UK born</td> <td>10 (33.3%)</td> <td>121 (34.6%)</td> </tr> <tr> <td colspan="3">HIV status</td> </tr> <tr> <td>Positive</td> <td>6 (20%)</td> <td>37 (10.6%)</td> </tr> <tr> <td>Negative or not known</td> <td>24 (80%)</td> <td>313 (89.4%)</td> </tr> <tr> <td colspan="3">Contact with drug-resistant TB</td> </tr> <tr> <td>Yes</td> <td>1 (3.3%)</td> <td>1 (0.3%)</td> </tr> <tr> <td>No</td> <td>29 (96.7%)</td> <td>349 (99.7%)</td> </tr> <tr> <td colspan="3">Site of infection</td> </tr> <tr> <td>Pulmonary</td> <td>20 (66.7%)</td> <td>196 (56%)</td> </tr> <tr> <td>Extrapulmonary</td> <td>10 (33.3%)</td> <td>138 (39.4%)</td> </tr> <tr> <td>Both</td> <td>0</td> <td>16 (4.6%)</td> </tr> <tr> <td colspan="3">Previous treatment</td> </tr> <tr> <td>Yes</td> <td>3 (10%)</td> <td>21 (6%)</td> </tr> <tr> <td>No</td> <td>27 (90%)</td> <td>329 (94%)</td> </tr> </tbody> </table>		Drug-resistant ^a n = 30 (7.9%)	Drug-susceptible n = 350 (92.1%)	Age, years			0–19	4 (13.3%)	29 (8.3%)	20–39	18 (60%)	198 (56.6%)	40–59	4 (13.3%)	67 (19.1%)	60–79	4 (13.3%)	38 (10.9%)	≥80	0	18 (5.1%)	Sex			Male	17 (56.7%)	182 (52%)	Female	13 (43.3%)	168 (48%)	Country of origin			High-incidence (drug resistance)	14 (46.7%)	185 (52.9%)	Low-incidence (drug resistance)	16 (53.3%)	165 (47.1%)	Date of arrival in the UK			<2000	9 (30%)	102 (29.1%)	≥2000	11 (36.7%)	127 (36.3%)	Missing or UK born	10 (33.3%)	121 (34.6%)	HIV status			Positive	6 (20%)	37 (10.6%)	Negative or not known	24 (80%)	313 (89.4%)	Contact with drug-resistant TB			Yes	1 (3.3%)	1 (0.3%)	No	29 (96.7%)	349 (99.7%)	Site of infection			Pulmonary	20 (66.7%)	196 (56%)	Extrapulmonary	10 (33.3%)	138 (39.4%)	Both	0	16 (4.6%)	Previous treatment			Yes	3 (10%)	21 (6%)	No	27 (90%)	329 (94%)
	Drug-resistant ^a n = 30 (7.9%)	Drug-susceptible n = 350 (92.1%)																																																																																											
Age, years																																																																																													
0–19	4 (13.3%)	29 (8.3%)																																																																																											
20–39	18 (60%)	198 (56.6%)																																																																																											
40–59	4 (13.3%)	67 (19.1%)																																																																																											
60–79	4 (13.3%)	38 (10.9%)																																																																																											
≥80	0	18 (5.1%)																																																																																											
Sex																																																																																													
Male	17 (56.7%)	182 (52%)																																																																																											
Female	13 (43.3%)	168 (48%)																																																																																											
Country of origin																																																																																													
High-incidence (drug resistance)	14 (46.7%)	185 (52.9%)																																																																																											
Low-incidence (drug resistance)	16 (53.3%)	165 (47.1%)																																																																																											
Date of arrival in the UK																																																																																													
<2000	9 (30%)	102 (29.1%)																																																																																											
≥2000	11 (36.7%)	127 (36.3%)																																																																																											
Missing or UK born	10 (33.3%)	121 (34.6%)																																																																																											
HIV status																																																																																													
Positive	6 (20%)	37 (10.6%)																																																																																											
Negative or not known	24 (80%)	313 (89.4%)																																																																																											
Contact with drug-resistant TB																																																																																													
Yes	1 (3.3%)	1 (0.3%)																																																																																											
No	29 (96.7%)	349 (99.7%)																																																																																											
Site of infection																																																																																													
Pulmonary	20 (66.7%)	196 (56%)																																																																																											
Extrapulmonary	10 (33.3%)	138 (39.4%)																																																																																											
Both	0	16 (4.6%)																																																																																											
Previous treatment																																																																																													
Yes	3 (10%)	21 (6%)																																																																																											
No	27 (90%)	329 (94%)																																																																																											
Location	Essex																																																																																												
Approach to analysis	<p>Differences in demographic and risk factors for drug-resistant tuberculosis were examined by univariable analysis. The association between drug resistance and the following variables was determined: age, gender, high incidence countries for drug resistance, date of arrival in the UK, HIV serostatus, previous treatment, exposure to drug-resistant tuberculosis, and site of infection.</p> <p>A multivariable logistic regression model was developed to examine the association between past treatment and drug resistance, adjusted for those variables mentioned above.</p>																																																																																												
Outcomes measures and effect size	<i>Risk factors for drug resistance in patients with tuberculosis</i>																																																																																												

^a Thirty-three drug-resistant isolates were cultured: 29 isoniazid-resistant, three multidrug-resistant, and one rifampin mono-resistant.

Melzer M, Gupta N, Petersen I, Cook S and Hall B (2010) Previous treatment in predicting drug-resistant tuberculosis in an area bordering East London, UK. International Journal of Infectious Diseases 14(8): e717-22																																		
Bibliographic reference																																		
	<table border="1"> <thead> <tr> <th><i>Risk factor</i></th> <th><i>Adjusted OR (95% CI)</i></th> <th><i>P-value</i></th> </tr> </thead> <tbody> <tr> <td>Previous treatment</td> <td>1.53 (0.41 to 5.62)</td> <td>0.52</td> </tr> <tr> <td>Age¹</td> <td>-</td> <td>0.46</td> </tr> <tr> <td>Sex</td> <td></td> <td></td> </tr> <tr> <td>Female</td> <td>0.70 (0.33 to 1.49)</td> <td>0.36</td> </tr> <tr> <td>Country of origin</td> <td></td> <td></td> </tr> <tr> <td>High incidence of drug resistance</td> <td>0.61 (0.25 to 1.47)</td> <td>0.27</td> </tr> <tr> <td>Date of arrival in the UK²</td> <td></td> <td></td> </tr> <tr> <td>≥2000 i.e. <3-6 years in the UK</td> <td>0.71 (0.27 to 1.87)</td> <td>0.48</td> </tr> <tr> <td>HIV-positive</td> <td>1.93 (0.70 to 5.23)</td> <td>0.19</td> </tr> <tr> <td>Previous exposure to drug resistant tuberculosis</td> <td>12.84 (0.68 to 240.2)</td> <td>0.09</td> </tr> </tbody> </table>	<i>Risk factor</i>	<i>Adjusted OR (95% CI)</i>	<i>P-value</i>	Previous treatment	1.53 (0.41 to 5.62)	0.52	Age ¹	-	0.46	Sex			Female	0.70 (0.33 to 1.49)	0.36	Country of origin			High incidence of drug resistance	0.61 (0.25 to 1.47)	0.27	Date of arrival in the UK ²			≥2000 i.e. <3-6 years in the UK	0.71 (0.27 to 1.87)	0.48	HIV-positive	1.93 (0.70 to 5.23)	0.19	Previous exposure to drug resistant tuberculosis	12.84 (0.68 to 240.2)	0.09
<i>Risk factor</i>	<i>Adjusted OR (95% CI)</i>	<i>P-value</i>																																
Previous treatment	1.53 (0.41 to 5.62)	0.52																																
Age ¹	-	0.46																																
Sex																																		
Female	0.70 (0.33 to 1.49)	0.36																																
Country of origin																																		
High incidence of drug resistance	0.61 (0.25 to 1.47)	0.27																																
Date of arrival in the UK ²																																		
≥2000 i.e. <3-6 years in the UK	0.71 (0.27 to 1.87)	0.48																																
HIV-positive	1.93 (0.70 to 5.23)	0.19																																
Previous exposure to drug resistant tuberculosis	12.84 (0.68 to 240.2)	0.09																																
Source of funding	No details provided																																	
Comments																																		
¹ Age was divided into quintiles and analysis for trend was performed ² Where date of arrival in the UK was not recorded, patients were assumed to be UK born Abbreviations: CI, confidence interval; OR, odds ratio																																		

Table 6: Neely, 2009

Neely F, Maguire H, Le Brun F, Davies A, Gelb D and Yates S (2010) High rate of transmission among contacts in large London outbreak of isoniazid mono-resistant tuberculosis. Journal of Public Health 32(1): 44-51	
Bibliographic reference	
Study type	Unmatched case-control
Study quality	Sample sufficiently represents the population of interest with regard to key characteristics? <i>yes</i> Loss to follow-up sufficiently unrelated to key characteristics? <i>unclear</i> Prognostic factor of interest adequately measured? <i>yes, although blinding not reported</i> Outcome of interest adequately measured? <i>yes, although blinding not reported</i> Important potential confounders appropriately accounted for? <i>multivariate analysis used, but unclear which confounders were controlled for</i> Statistical analysis appropriate? <i>yes, although analyses not reported for number of drug-using cases to whom contact</i>

Bibliographic reference	Neely F, Maguire H, Le Brun F, Davies A, Gelb D and Yates S (2010) High rate of transmission among contacts in large London outbreak of isoniazid mono-resistant tuberculosis. Journal of Public Health 32(1): 44-51																																
	<i>exposed, which was recorded and reported in population characteristics</i>																																
Number of patients	n = 612 (87 of the 1 st 100 cases ¹ plus 525 people with tuberculosis among the contacts) Outcome data available for 355 ² <ul style="list-style-type: none"> • isoniazid-resistant tuberculosis = 127 • fully sensitive tuberculosis = 228 																																
Patient characteristics	<p><i>Recruitment</i> Screening of community (social and household) contacts of the first 100 confirmed cases reported during an outbreak of isoniazid monoresistant tuberculosis in London</p> <p><i>Exclusions</i> Institutional contacts (i.e. school, hospital, work or prison inmates) could not be included in this analysis, as screening denominators and outcome records were dispersed through many different organizations and very incomplete</p> <p><i>Study group(s)</i> Patients in whom an isolate of <i>M. tuberculosis</i> was cultured that was monoresistant to isoniazid and had the characteristic 15-band pattern of the outbreak strain on RFLP typing, or clinical cases that were epidemiologically linked to a case, had clinical signs or symptoms consistent with tuberculosis and were treated for isoniazid-resistant tuberculosis in the absence of a culture result</p> <p><i>Comparator</i> Patients with drug susceptible tuberculosis</p> <p><i>Population characteristics</i></p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th rowspan="2"></th> <th rowspan="2">Cases, n (%)</th> <th colspan="2">Controls, n (%)</th> </tr> <tr> <th>Receiving chemoprophylaxis</th> <th>Discharge clear</th> </tr> </thead> <tbody> <tr> <td>Date of birth</td> <td></td> <td></td> <td></td> </tr> <tr> <td> 1980–2003</td> <td>14 (9.5)</td> <td>32 (21.8)</td> <td>101 (68.7)</td> </tr> <tr> <td> 1960–1980</td> <td>14 (12.6)</td> <td>8 (7.2)</td> <td>89 (80.2)</td> </tr> <tr> <td> 1920–1960</td> <td>4 (6.2)</td> <td>1 (1.5)</td> <td>60 (92.3)</td> </tr> <tr> <td> Missing</td> <td>8</td> <td>4</td> <td>20</td> </tr> <tr> <td> Total</td> <td>40</td> <td>45</td> <td>270</td> </tr> </tbody> </table>				Cases, n (%)	Controls, n (%)		Receiving chemoprophylaxis	Discharge clear	Date of birth				1980–2003	14 (9.5)	32 (21.8)	101 (68.7)	1960–1980	14 (12.6)	8 (7.2)	89 (80.2)	1920–1960	4 (6.2)	1 (1.5)	60 (92.3)	Missing	8	4	20	Total	40	45	270
	Cases, n (%)	Controls, n (%)																															
		Receiving chemoprophylaxis	Discharge clear																														
Date of birth																																	
1980–2003	14 (9.5)	32 (21.8)	101 (68.7)																														
1960–1980	14 (12.6)	8 (7.2)	89 (80.2)																														
1920–1960	4 (6.2)	1 (1.5)	60 (92.3)																														
Missing	8	4	20																														
Total	40	45	270																														

Bibliographic reference	Neely F, Maguire H, Le Brun F, Davies A, Gelb D and Yates S (2010) High rate of transmission among contacts in large London outbreak of isoniazid mono-resistant tuberculosis. <i>Journal of Public Health</i> 32(1): 44-51			
Gender				
Male	22 (15.1)	23 (15.7)	101 (69.2)	
Female	17 (9.1)	20 (10.8)	149 (80.1)	
Missing	1	2	20	
Total	40	45	270	
Cases to whom contact exposed				
1	25 (8.2)	31 (10.2)	248 (81.6)	
≥2	15 (29.4)	14 (27.5)	22 (43.1)	
Total	40	45	270	
Nature of contact				
Household	26 (20.2)	23 (17.8)	80 (62.0)	
Social	13 (6.1)	20 (9.3)	181 (84.6)	
Missing	1	2	9	
Total	40	45	270	
Degree of exposure				
Close	31 (16.9)	27 (14.8)	125 (68.3)	
Casual	4 (2.9)	14 (10.2)	119 (86.9)	
Missing	5	4	26	
Total	40	45	270	
Sputum smear positive cases to whom contact exposed				
≥1	30 (14.1)	29 (13.7)	153 (72.2)	
0	8 (7.3)	13 (11.8)	89 (80.9)	
Missing	2	3	28	
Total	40	45	270	
Number of prison cases to whom contact exposed				
≥1	21 (18.4)	24 (21.1)	69 (60.5)	
0	16 (10.5)	10 (6.6)	126 (82.9)	
Missing	3	11	75	
Total	40	45	270	

Bibliographic reference	Neely F, Maguire H, Le Brun F, Davies A, Gelb D and Yates S (2010) High rate of transmission among contacts in large London outbreak of isoniazid mono-resistant tuberculosis. <i>Journal of Public Health</i> 32(1): 44-51																																						
	<table border="1"> <thead> <tr> <th colspan="4">Number of drug-using cases to whom contact exposed</th> </tr> </thead> <tbody> <tr> <td>≥1</td> <td>29 (16.7)</td> <td>31 (17.8)</td> <td>114 (65.5)</td> </tr> <tr> <td>0</td> <td>2 (2.9)</td> <td>7 (10.1)</td> <td>60 (87.0)</td> </tr> <tr> <td>Missing</td> <td>9</td> <td>7</td> <td>96</td> </tr> <tr> <td>Total</td> <td>40</td> <td>45</td> <td>270</td> </tr> </tbody> </table>			Number of drug-using cases to whom contact exposed				≥1	29 (16.7)	31 (17.8)	114 (65.5)	0	2 (2.9)	7 (10.1)	60 (87.0)	Missing	9	7	96	Total	40	45	270																
Number of drug-using cases to whom contact exposed																																							
≥1	29 (16.7)	31 (17.8)	114 (65.5)																																				
0	2 (2.9)	7 (10.1)	60 (87.0)																																				
Missing	9	7	96																																				
Total	40	45	270																																				
Location	London																																						
Approach to analysis	<p>Univariate analysis of risk factors for outcome of screening showed a high degree of correlation between the following variables: young contacts, household and close contacts as well as those in contact with prisoners or drug-using cases. Because of this, for the multivariable model, the authors used the variable whether contacts were exposed to more than one case, but did not use the variables indicating contact with sputum smear-positive cases, prison or drug-using case; further reasons for their exclusion from the multivariable analysis were that the univariate analysis revealed only a weak, non-statistically significant association between contact with a sputum smear-positive case and transmission of disease (contrary to other evidence and discussed later in the paper), and that for 30% of cases it was unknown whether they were prisoners or drug users.</p> <p>A strong statistical association was found between the degree of exposure (close or casual) and nature of contact (household or social) ($P < 0.001$); this was inevitably the result of classifying all household contacts as close – therefore, the variable describing the degree of exposure was kept in the main multivariable model and nature of contact excluded.</p>																																						
Outcomes measures and effect size	<p><i>Risk factors for isoniazid resistance in patients with tuberculosis</i></p> <table border="1"> <thead> <tr> <th>Risk factor</th> <th>Adjusted OR (95% CI)</th> <th>Reference</th> </tr> </thead> <tbody> <tr> <td>Age³:</td> <td></td> <td></td> </tr> <tr> <td>25-44 years</td> <td>1.7 (0.5 to 6.3)</td> <td>≥45 years</td> </tr> <tr> <td>≤24 years</td> <td>2.1 (0.6 to 7.7)</td> <td>≥45 years</td> </tr> <tr> <td>Gender:</td> <td></td> <td></td> </tr> <tr> <td>Male</td> <td>2.7 (1.1 to 6.6)</td> <td>Female</td> </tr> <tr> <td>Degree of exposure:</td> <td></td> <td></td> </tr> <tr> <td>Close⁴</td> <td>6.2 (1.7 to 21.8)</td> <td>Casual⁴</td> </tr> <tr> <td>Cases to whom contact was exposed:</td> <td></td> <td></td> </tr> <tr> <td>≥2</td> <td>3.1 (1.1 to 8.4)</td> <td>1</td> </tr> <tr> <td>Sputum smear positive cases to whom contact was exposed:</td> <td></td> <td></td> </tr> <tr> <td>≥1</td> <td>2.2 (0.8 to 6.2)</td> <td>0</td> </tr> </tbody> </table>			Risk factor	Adjusted OR (95% CI)	Reference	Age ³ :			25-44 years	1.7 (0.5 to 6.3)	≥45 years	≤24 years	2.1 (0.6 to 7.7)	≥45 years	Gender:			Male	2.7 (1.1 to 6.6)	Female	Degree of exposure:			Close ⁴	6.2 (1.7 to 21.8)	Casual ⁴	Cases to whom contact was exposed:			≥2	3.1 (1.1 to 8.4)	1	Sputum smear positive cases to whom contact was exposed:			≥1	2.2 (0.8 to 6.2)	0
Risk factor	Adjusted OR (95% CI)	Reference																																					
Age ³ :																																							
25-44 years	1.7 (0.5 to 6.3)	≥45 years																																					
≤24 years	2.1 (0.6 to 7.7)	≥45 years																																					
Gender:																																							
Male	2.7 (1.1 to 6.6)	Female																																					
Degree of exposure:																																							
Close ⁴	6.2 (1.7 to 21.8)	Casual ⁴																																					
Cases to whom contact was exposed:																																							
≥2	3.1 (1.1 to 8.4)	1																																					
Sputum smear positive cases to whom contact was exposed:																																							
≥1	2.2 (0.8 to 6.2)	0																																					

Bibliographic reference	Neely F, Maguire H, Le Brun F, Davies A, Gelb D and Yates S (2010) High rate of transmission among contacts in large London outbreak of isoniazid mono-resistant tuberculosis. Journal of Public Health 32(1): 44-51								
Source of funding	No details provided								
Comments	Study aim: for a continuing London outbreak of isoniazid mono-resistant tuberculosis, the authors aimed to determine the rate of transmission of same strain TB to contacts, and to identify which contacts were most at risk of becoming cases with a view to informing future contact tracing strategies								
<p>¹ Exclusions: 6 institutional contacts; 3 for whom no information was given by the chest clinic to the research group; 4 cases who did not report any contacts</p> <p>² Exclusions amongst contacts: no outcome or demographic data available for 24; 79 did not attend; 67 moved districts</p> <p>³ Converted from 'date of birth' by reviewer:</p> <table border="1"> <thead> <tr> <th><i>Date of birth</i></th> <th><i>Approximate age groups</i></th> </tr> </thead> <tbody> <tr> <td>1920-60</td> <td>≥45 years</td> </tr> <tr> <td>1960-80</td> <td>25-44 years</td> </tr> <tr> <td>1980-2003</td> <td>≤24 years</td> </tr> </tbody> </table> <p>⁴ The degree of exposure the contact had with the case was defined and categorized as minimal (1-2 hours), moderate (several hours) or close (days); contacts with minimal or moderate contact were grouped together and their exposure classified as casual; household contacts were considered to have had close contact</p>		<i>Date of birth</i>	<i>Approximate age groups</i>	1920-60	≥45 years	1960-80	25-44 years	1980-2003	≤24 years
<i>Date of birth</i>	<i>Approximate age groups</i>								
1920-60	≥45 years								
1960-80	25-44 years								
1980-2003	≤24 years								
Abbreviations: CI, confidence interval; OR, odds ratio; RFLP, restriction fragment length polymorphism									

Table 7: Pritchard, 2003

Bibliographic reference	Pritchard AJ, Hayward AC, Monk PN and Neal KR (2003) Risk factors for drug resistant tuberculosis in Leicestershire--poor adherence to treatment remains an important cause of resistance. Epidemiology and Infection 130(3): 481-3
Study type	Case-control
Study quality	<p>Sample sufficiently represents the population of interest with regard to key characteristics? <i>yes</i></p> <p>Loss to follow-up sufficiently unrelated to key characteristics? <i>yes</i></p> <p>Prognostic factor of interest adequately measured? <i>yes, although blinding unclear and authors had to rely on others' notes</i></p> <p>Outcome of interest adequately measured? <i>yes, although blinding unclear</i></p> <p>Important potential confounders appropriately accounted for? <i>cases and controls were matched on ethnic group, gender and age group; multivariate analysis used, but unclear which confounders were controlled for</i></p> <p>Statistical analysis appropriate? <i>yes</i></p>

Bibliographic reference	Pritchard AJ, Hayward AC, Monk PN and Neal KR (2003) Risk factors for drug resistant tuberculosis in Leicestershire--poor adherence to treatment remains an important cause of resistance. <i>Epidemiology and Infection</i> 130(3): 481-3																																									
Number of patients	n = 104 • tuberculosis resistant to any first line drug = 23 • fully sensitive tuberculosis = 81																																									
Patient characteristics	<p><i>Study group(s)</i> All patients with culture confirmed tuberculosis which was resistant to any first line drug between 1993 and 1998, living in Leicestershire</p> <p><i>Comparator</i> All patients with fully sensitive culture confirmed tuberculosis between 1993 and 1998, living in Leicestershire</p> <p>Cases and controls were matched on ethnic group, gender and age group</p> <p><i>Drug susceptibility testing</i> Technique unclear</p> <p><i>Population characteristics</i></p> <table border="1" data-bbox="976 879 1841 1394"> <thead> <tr> <th data-bbox="976 879 1525 991">Risk factor</th> <th data-bbox="1525 879 1727 991">Resistant n = 23 (%)</th> <th data-bbox="1727 879 1841 991">Sensitive n = 81 (%)</th> </tr> </thead> <tbody> <tr> <td data-bbox="976 991 1525 1031">Poor adherence* recorded in notes</td> <td data-bbox="1525 991 1727 1031">11 (47.8)</td> <td data-bbox="1727 991 1841 1031">12 (14.8)</td> </tr> <tr> <td data-bbox="976 1031 1525 1070">No evidence of poor adherence in notes</td> <td data-bbox="1525 1031 1727 1070">12 (52.2)</td> <td data-bbox="1727 1031 1841 1070">69 (85.2)</td> </tr> <tr> <td data-bbox="976 1070 1525 1110">Previous TB recorded in notes</td> <td data-bbox="1525 1070 1727 1110">8 (34.8)</td> <td data-bbox="1727 1070 1841 1110">10 (12.3)</td> </tr> <tr> <td data-bbox="976 1110 1525 1150">No evidence of previous TB in notes</td> <td data-bbox="1525 1110 1727 1150">15 (65.2)</td> <td data-bbox="1727 1110 1841 1150">71 (87.7)</td> </tr> <tr> <td data-bbox="976 1150 1525 1190">Non-pulmonary</td> <td data-bbox="1525 1150 1727 1190">10 (45.5)</td> <td data-bbox="1727 1150 1841 1190">47 (58.0)</td> </tr> <tr> <td data-bbox="976 1190 1525 1230">Pulmonary</td> <td data-bbox="1525 1190 1727 1230">12 (54.5)</td> <td data-bbox="1727 1190 1841 1230">34 (42.0)</td> </tr> <tr> <td data-bbox="976 1230 1525 1270">Foreign birth recorded in notes</td> <td data-bbox="1525 1230 1727 1270">13 (56.5)</td> <td data-bbox="1727 1230 1841 1270">53 (65.4)</td> </tr> <tr> <td data-bbox="976 1270 1525 1310">No evidence of foreign birth in notes</td> <td data-bbox="1525 1270 1727 1310">10 (43.5)</td> <td data-bbox="1727 1270 1841 1310">28 (34.6)</td> </tr> <tr> <td data-bbox="976 1310 1525 1350">Foreign travel† recorded in notes</td> <td data-bbox="1525 1310 1727 1350">13 (56.5)</td> <td data-bbox="1727 1310 1841 1350">35 (43.2)</td> </tr> <tr> <td data-bbox="976 1350 1525 1390">No evidence of foreign travel in notes</td> <td data-bbox="1525 1350 1727 1390">10 (43.5)</td> <td data-bbox="1727 1350 1841 1390">46 (56.8)</td> </tr> <tr> <td data-bbox="976 1390 1525 1430">Recent immigration‡ recorded in notes</td> <td data-bbox="1525 1390 1727 1430">2 (8.7)</td> <td data-bbox="1727 1390 1841 1430">6 (7.4)</td> </tr> <tr> <td data-bbox="976 1430 1525 1469">No evidence of recent immigration in notes</td> <td data-bbox="1525 1430 1727 1469">21 (91.3)</td> <td data-bbox="1727 1430 1841 1469">75 (92.6)</td> </tr> </tbody> </table>			Risk factor	Resistant n = 23 (%)	Sensitive n = 81 (%)	Poor adherence* recorded in notes	11 (47.8)	12 (14.8)	No evidence of poor adherence in notes	12 (52.2)	69 (85.2)	Previous TB recorded in notes	8 (34.8)	10 (12.3)	No evidence of previous TB in notes	15 (65.2)	71 (87.7)	Non-pulmonary	10 (45.5)	47 (58.0)	Pulmonary	12 (54.5)	34 (42.0)	Foreign birth recorded in notes	13 (56.5)	53 (65.4)	No evidence of foreign birth in notes	10 (43.5)	28 (34.6)	Foreign travel† recorded in notes	13 (56.5)	35 (43.2)	No evidence of foreign travel in notes	10 (43.5)	46 (56.8)	Recent immigration‡ recorded in notes	2 (8.7)	6 (7.4)	No evidence of recent immigration in notes	21 (91.3)	75 (92.6)
Risk factor	Resistant n = 23 (%)	Sensitive n = 81 (%)																																								
Poor adherence* recorded in notes	11 (47.8)	12 (14.8)																																								
No evidence of poor adherence in notes	12 (52.2)	69 (85.2)																																								
Previous TB recorded in notes	8 (34.8)	10 (12.3)																																								
No evidence of previous TB in notes	15 (65.2)	71 (87.7)																																								
Non-pulmonary	10 (45.5)	47 (58.0)																																								
Pulmonary	12 (54.5)	34 (42.0)																																								
Foreign birth recorded in notes	13 (56.5)	53 (65.4)																																								
No evidence of foreign birth in notes	10 (43.5)	28 (34.6)																																								
Foreign travel† recorded in notes	13 (56.5)	35 (43.2)																																								
No evidence of foreign travel in notes	10 (43.5)	46 (56.8)																																								
Recent immigration‡ recorded in notes	2 (8.7)	6 (7.4)																																								
No evidence of recent immigration in notes	21 (91.3)	75 (92.6)																																								
Location	Leicestershire																																									

Bibliographic reference	Pritchard AJ, Hayward AC, Monk PN and Neal KR (2003) Risk factors for drug resistant tuberculosis in Leicestershire--poor adherence to treatment remains an important cause of resistance. <i>Epidemiology and Infection</i> 130(3): 481-3			
Approach to analysis	Multivariate analysis			
Outcomes measures and effect size	<i>Risk factors for first line drug resistance in patients with tuberculosis</i>			
	<i>Risk factor</i>	<i>Reference</i>	<i>Adjusted OR (95% CI)</i>	<i>P</i>
	Poor adherence	No evidence of poor adherence	4.8 (1.6 to 14.4)	0.005
	Previous history of tuberculosis	No previous history of tuberculosis	3.7 (1.2 to 11.8)	0.022
	Pulmonary	Extrapulmonary	Not provided; authors state not significant	>0.05
	Foreign birth	UK birth	Not provided; authors state not significant	>0.05
	Foreign travel	No evidence of foreign travel	Not provided; authors state not significant	>0.05
	Recent immigration	No evidence of recent immigration	Not provided; authors state not significant	>0.05
Source of funding	Leicestershire Health Authority			
Comments				
Abbreviations: CI, confidence interval; OR, odds ratio				

Table 8: Story, 2007

Bibliographic reference	Story A, Murad S, Roberts W, Verheyen M, Hayward AC; London Tuberculosis Nurses Network (2007) Tuberculosis in London: the importance of homelessness, problem drug use and prison. <i>Thorax</i> 62(8): 667-71
Study type	Observational
Study quality	Sample sufficiently represents the population of interest with regard to key characteristics? <i>yes</i> Loss to follow-up sufficiently unrelated to key characteristics? <i>unclear</i> Prognostic factor of interest adequately measured? <i>yes, although blinding not reported</i> Outcome of interest adequately measured? <i>yes, although blinding not reported</i>

Bibliographic reference	Story A, Murad S, Roberts W, Verheyen M, Hayward AC; London Tuberculosis Nurses Network (2007) Tuberculosis in London: the importance of homelessness, problem drug use and prison. <i>Thorax</i> 62(8): 667-71
	<p>Important potential confounders appropriately accounted for? <i>multivariate analysis used, but unclear which confounders were controlled for</i></p> <p>Statistical analysis appropriate? <i>yes, although analyses not reported for a number of variables recorded and reported in population characteristics</i></p>
Number of patients	<p>1995 eligible patients Data available for 1941</p> <ul style="list-style-type: none"> • any drug resistance = 234 • multidrug resistance = 67 • isoniazid resistance = 167 • fully sensitive tuberculosis = 1473
Patient characteristics	<p><i>Study group(s)</i> All patients with drug resistant tuberculosis living in London who were or should have been on treatment on 1 July 2003 Drug resistance was divided into</p> <ul style="list-style-type: none"> • multidrug resistance (resistant to at least isoniazid and rifampicin) • isoniazid resistant strains that were part of the London outbreak (defined as patients resident in London at the time of their diagnosis with isolates of Mycobacterium tuberculosis resistant to isoniazid that had the outbreak RFLP pattern) • isoniazid resistant strains that were not part of the outbreak <p><i>Comparator</i> All patients with fully sensitive tuberculosis living in London who were or should have been on treatment on 1 July 2003</p> <p><i>Exclusion</i> Cases subsequently found not to have tuberculosis</p> <p><i>Population characteristics</i></p>

Bibliographic reference		Story A, Murad S, Roberts W, Verheyen M, Hayward AC; London Tuberculosis Nurses Network (2007) Tuberculosis in London: the importance of homelessness, problem drug use and prison. Thorax 62(8): 667-71																																																																																																																																																																																
	<table border="1"> <thead> <tr> <th>Patient characteristics</th> <th>n</th> <th>Culture confirmed n (%)</th> <th>Sputum smear positive n (%)</th> <th>Any drug resistance n (%)</th> <th>MDRTB n (%)</th> <th>Isoniazid resistant (non-outbreak) n (%)</th> <th>Isoniazid resistant (outbreak) n (%)</th> </tr> </thead> <tbody> <tr><td>Overall</td><td>1941</td><td>1121 (57.8%)</td><td>381 (19.6%)</td><td>234 (20.9%)</td><td>67 (6.0%)</td><td>129 (11.5%)</td><td>38 (3.4%)</td></tr> <tr><td>Age 0-14</td><td>92</td><td>29 (31.5%)</td><td>5 (5.4%)</td><td>6 (20.6%)</td><td>2 (6.9%)</td><td>3 (10.3%)</td><td>1 (3.4%)</td></tr> <tr><td>Age 15-29</td><td>718</td><td>444 (61.8%)</td><td>158 (22.0%)</td><td>97 (21.8%)</td><td>27 (6.1%)</td><td>57 (12.8%)</td><td>13 (2.9%)</td></tr> <tr><td>Age 30-59</td><td>919</td><td>536 (58.3%)</td><td>187 (20.3%)</td><td>116 (21.6%)</td><td>32 (6.0%)</td><td>61 (11.4%)</td><td>23 (4.3%)</td></tr> <tr><td>Age 60+</td><td>203</td><td>108 (53.2%)</td><td>31 (15.3%)</td><td>13 (12.0%)</td><td>5 (4.6%)</td><td>7 (6.5%)</td><td>1 (0.9%)</td></tr> <tr><td>Male</td><td>1064</td><td>637 (59.9%)</td><td>231 (21.7%)</td><td>139 (21.8%)</td><td>41 (6.4%)</td><td>74 (11.6%)</td><td>24 (3.8%)</td></tr> <tr><td>Female</td><td>847</td><td>467 (55.1%)</td><td>147 (17.4%)</td><td>94 (20.1%)</td><td>26 (5.6%)</td><td>54 (11.6%)</td><td>14 (3.0%)</td></tr> <tr><td>Foreign born</td><td>1548</td><td>902 (58.3%)</td><td>227 (14.7%)</td><td>179 (19.8%)</td><td>59 (6.5%)</td><td>106 (11.8%)</td><td>14 (1.6%)</td></tr> <tr><td>UK born</td><td>376</td><td>206 (54.8%)</td><td>100 (26.6%)</td><td>52 (25.2%)</td><td>6 (2.9%)</td><td>23 (11.2%)</td><td>23 (11.2%)</td></tr> <tr><td>Recent migrant (<1 year)</td><td>295</td><td>172 (58.3%)</td><td>54 (18.3%)</td><td>30 (17.4%)</td><td>10 (5.8%)</td><td>19 (11.0%)</td><td>1 (0.6%)</td></tr> <tr><td>White</td><td>303</td><td>188 (62.0%)</td><td>85 (28.1%)</td><td>34 (18.1%)</td><td>6 (3.2%)</td><td>19 (10.0%)</td><td>9 (4.8%)</td></tr> <tr><td>South Asian</td><td>650</td><td>339 (52.2%)</td><td>79 (12.2%)</td><td>52 (15.3%)</td><td>16 (4.7%)</td><td>33 (9.7%)</td><td>3 (0.9%)</td></tr> <tr><td>Black African</td><td>748</td><td>449 (60.0%)</td><td>150 (20.1%)</td><td>100 (22.3%)</td><td>37 (8.2%)</td><td>59 (13.1%)</td><td>4 (0.9%)</td></tr> <tr><td>Black Caribbean</td><td>92</td><td>64 (69.6%)</td><td>33 (35.9%)</td><td>25 (39.1%)</td><td>2 (3.2%)</td><td>6 (9.4%)</td><td>17 (26.6%)</td></tr> <tr><td>Other</td><td>83</td><td>48 (57.8%)</td><td>19 (22.9%)</td><td>15 (31.3%)</td><td>5 (10.4%)</td><td>8 (16.7%)</td><td>2 (4.2%)</td></tr> <tr><td>Previous TB</td><td>202</td><td>111 (55.0%)</td><td>42 (20.8%)</td><td>47 (42.3%)</td><td>26 (23.4%)</td><td>15 (13.5%)</td><td>6 (5.4%)</td></tr> <tr><td>PDU</td><td>248</td><td>176 (71.0%)</td><td>97 (39.1%)</td><td>58 (33.0%)</td><td>11 (6.3%)</td><td>20 (11.4%)</td><td>27 (15.3%)</td></tr> <tr><td>Alcohol</td><td>156</td><td>111 (71.2%)</td><td>64 (41.0%)</td><td>34 (30.6%)</td><td>5 (4.5%)</td><td>11 (9.9%)</td><td>18 (16.2%)</td></tr> <tr><td>Prison during treatment</td><td>74</td><td>55 (74.3%)</td><td>29 (39.2%)</td><td>30 (54.5%)</td><td>8 (14.5%)</td><td>3 (5.5%)</td><td>19 (25.7%)</td></tr> <tr><td>Homeless during treatment</td><td>110</td><td>77 (70.0%)</td><td>42 (38.2%)</td><td>30 (39.0%)</td><td>5 (6.5%)</td><td>13 (16.9%)</td><td>12 (15.6%)</td></tr> <tr><td>Prison or homeless or PDU</td><td>321</td><td>221 (68.8%)</td><td>115 (35.8%)</td><td>67 (30.3%)</td><td>14 (6.3%)</td><td>26 (11.8%)</td><td>27 (12.2%)</td></tr> </tbody> </table>	Patient characteristics	n	Culture confirmed n (%)	Sputum smear positive n (%)	Any drug resistance n (%)	MDRTB n (%)	Isoniazid resistant (non-outbreak) n (%)	Isoniazid resistant (outbreak) n (%)	Overall	1941	1121 (57.8%)	381 (19.6%)	234 (20.9%)	67 (6.0%)	129 (11.5%)	38 (3.4%)	Age 0-14	92	29 (31.5%)	5 (5.4%)	6 (20.6%)	2 (6.9%)	3 (10.3%)	1 (3.4%)	Age 15-29	718	444 (61.8%)	158 (22.0%)	97 (21.8%)	27 (6.1%)	57 (12.8%)	13 (2.9%)	Age 30-59	919	536 (58.3%)	187 (20.3%)	116 (21.6%)	32 (6.0%)	61 (11.4%)	23 (4.3%)	Age 60+	203	108 (53.2%)	31 (15.3%)	13 (12.0%)	5 (4.6%)	7 (6.5%)	1 (0.9%)	Male	1064	637 (59.9%)	231 (21.7%)	139 (21.8%)	41 (6.4%)	74 (11.6%)	24 (3.8%)	Female	847	467 (55.1%)	147 (17.4%)	94 (20.1%)	26 (5.6%)	54 (11.6%)	14 (3.0%)	Foreign born	1548	902 (58.3%)	227 (14.7%)	179 (19.8%)	59 (6.5%)	106 (11.8%)	14 (1.6%)	UK born	376	206 (54.8%)	100 (26.6%)	52 (25.2%)	6 (2.9%)	23 (11.2%)	23 (11.2%)	Recent migrant (<1 year)	295	172 (58.3%)	54 (18.3%)	30 (17.4%)	10 (5.8%)	19 (11.0%)	1 (0.6%)	White	303	188 (62.0%)	85 (28.1%)	34 (18.1%)	6 (3.2%)	19 (10.0%)	9 (4.8%)	South Asian	650	339 (52.2%)	79 (12.2%)	52 (15.3%)	16 (4.7%)	33 (9.7%)	3 (0.9%)	Black African	748	449 (60.0%)	150 (20.1%)	100 (22.3%)	37 (8.2%)	59 (13.1%)	4 (0.9%)	Black Caribbean	92	64 (69.6%)	33 (35.9%)	25 (39.1%)	2 (3.2%)	6 (9.4%)	17 (26.6%)	Other	83	48 (57.8%)	19 (22.9%)	15 (31.3%)	5 (10.4%)	8 (16.7%)	2 (4.2%)	Previous TB	202	111 (55.0%)	42 (20.8%)	47 (42.3%)	26 (23.4%)	15 (13.5%)	6 (5.4%)	PDU	248	176 (71.0%)	97 (39.1%)	58 (33.0%)	11 (6.3%)	20 (11.4%)	27 (15.3%)	Alcohol	156	111 (71.2%)	64 (41.0%)	34 (30.6%)	5 (4.5%)	11 (9.9%)	18 (16.2%)	Prison during treatment	74	55 (74.3%)	29 (39.2%)	30 (54.5%)	8 (14.5%)	3 (5.5%)	19 (25.7%)	Homeless during treatment	110	77 (70.0%)	42 (38.2%)	30 (39.0%)	5 (6.5%)	13 (16.9%)	12 (15.6%)	Prison or homeless or PDU	321	221 (68.8%)	115 (35.8%)	67 (30.3%)	14 (6.3%)	26 (11.8%)	27 (12.2%)	
Patient characteristics	n	Culture confirmed n (%)	Sputum smear positive n (%)	Any drug resistance n (%)	MDRTB n (%)	Isoniazid resistant (non-outbreak) n (%)	Isoniazid resistant (outbreak) n (%)																																																																																																																																																																											
Overall	1941	1121 (57.8%)	381 (19.6%)	234 (20.9%)	67 (6.0%)	129 (11.5%)	38 (3.4%)																																																																																																																																																																											
Age 0-14	92	29 (31.5%)	5 (5.4%)	6 (20.6%)	2 (6.9%)	3 (10.3%)	1 (3.4%)																																																																																																																																																																											
Age 15-29	718	444 (61.8%)	158 (22.0%)	97 (21.8%)	27 (6.1%)	57 (12.8%)	13 (2.9%)																																																																																																																																																																											
Age 30-59	919	536 (58.3%)	187 (20.3%)	116 (21.6%)	32 (6.0%)	61 (11.4%)	23 (4.3%)																																																																																																																																																																											
Age 60+	203	108 (53.2%)	31 (15.3%)	13 (12.0%)	5 (4.6%)	7 (6.5%)	1 (0.9%)																																																																																																																																																																											
Male	1064	637 (59.9%)	231 (21.7%)	139 (21.8%)	41 (6.4%)	74 (11.6%)	24 (3.8%)																																																																																																																																																																											
Female	847	467 (55.1%)	147 (17.4%)	94 (20.1%)	26 (5.6%)	54 (11.6%)	14 (3.0%)																																																																																																																																																																											
Foreign born	1548	902 (58.3%)	227 (14.7%)	179 (19.8%)	59 (6.5%)	106 (11.8%)	14 (1.6%)																																																																																																																																																																											
UK born	376	206 (54.8%)	100 (26.6%)	52 (25.2%)	6 (2.9%)	23 (11.2%)	23 (11.2%)																																																																																																																																																																											
Recent migrant (<1 year)	295	172 (58.3%)	54 (18.3%)	30 (17.4%)	10 (5.8%)	19 (11.0%)	1 (0.6%)																																																																																																																																																																											
White	303	188 (62.0%)	85 (28.1%)	34 (18.1%)	6 (3.2%)	19 (10.0%)	9 (4.8%)																																																																																																																																																																											
South Asian	650	339 (52.2%)	79 (12.2%)	52 (15.3%)	16 (4.7%)	33 (9.7%)	3 (0.9%)																																																																																																																																																																											
Black African	748	449 (60.0%)	150 (20.1%)	100 (22.3%)	37 (8.2%)	59 (13.1%)	4 (0.9%)																																																																																																																																																																											
Black Caribbean	92	64 (69.6%)	33 (35.9%)	25 (39.1%)	2 (3.2%)	6 (9.4%)	17 (26.6%)																																																																																																																																																																											
Other	83	48 (57.8%)	19 (22.9%)	15 (31.3%)	5 (10.4%)	8 (16.7%)	2 (4.2%)																																																																																																																																																																											
Previous TB	202	111 (55.0%)	42 (20.8%)	47 (42.3%)	26 (23.4%)	15 (13.5%)	6 (5.4%)																																																																																																																																																																											
PDU	248	176 (71.0%)	97 (39.1%)	58 (33.0%)	11 (6.3%)	20 (11.4%)	27 (15.3%)																																																																																																																																																																											
Alcohol	156	111 (71.2%)	64 (41.0%)	34 (30.6%)	5 (4.5%)	11 (9.9%)	18 (16.2%)																																																																																																																																																																											
Prison during treatment	74	55 (74.3%)	29 (39.2%)	30 (54.5%)	8 (14.5%)	3 (5.5%)	19 (25.7%)																																																																																																																																																																											
Homeless during treatment	110	77 (70.0%)	42 (38.2%)	30 (39.0%)	5 (6.5%)	13 (16.9%)	12 (15.6%)																																																																																																																																																																											
Prison or homeless or PDU	321	221 (68.8%)	115 (35.8%)	67 (30.3%)	14 (6.3%)	26 (11.8%)	27 (12.2%)																																																																																																																																																																											
Location	London																																																																																																																																																																																	
Approach to analysis	Logistic regression analysis was used to calculate univariate odds ratios, 95% confidence intervals and p values Multiple logistic regression models (backwards elimination) were used to control for confounding using robust standard errors to account for clustering at the clinic level																																																																																																																																																																																	
Outcomes measures and effect size	<p><i>Risk factors for any drug resistance in patients with tuberculosis</i></p> <table border="1"> <thead> <tr> <th>Risk factor</th> <th>Adjusted OR (95% CI)</th> </tr> </thead> <tbody> <tr> <td>Age:</td> <td></td> </tr> <tr> <td>0-14 years</td> <td>1.0 (0.3 to 3.4)</td> </tr> <tr> <td>15-29 years</td> <td>1.0 (0.8 to 1.6)</td> </tr> <tr> <td>30-59 years</td> <td>Reference</td> </tr> <tr> <td>≥60 years</td> <td>0.6 (0.4 to 1.0)</td> </tr> <tr> <td>Male</td> <td>1.0 (0.7 to 1.4)</td> </tr> </tbody> </table>	Risk factor	Adjusted OR (95% CI)	Age:		0-14 years	1.0 (0.3 to 3.4)	15-29 years	1.0 (0.8 to 1.6)	30-59 years	Reference	≥60 years	0.6 (0.4 to 1.0)	Male	1.0 (0.7 to 1.4)																																																																																																																																																																			
Risk factor	Adjusted OR (95% CI)																																																																																																																																																																																	
Age:																																																																																																																																																																																		
0-14 years	1.0 (0.3 to 3.4)																																																																																																																																																																																	
15-29 years	1.0 (0.8 to 1.6)																																																																																																																																																																																	
30-59 years	Reference																																																																																																																																																																																	
≥60 years	0.6 (0.4 to 1.0)																																																																																																																																																																																	
Male	1.0 (0.7 to 1.4)																																																																																																																																																																																	

Bibliographic reference	Story A, Murad S, Roberts W, Verheyen M, Hayward AC; London Tuberculosis Nurses Network (2007) Tuberculosis in London: the importance of homelessness, problem drug use and prison. Thorax 62(8): 667-71	
	Born in the UK	-
	Ethnicity:	
	White	Reference
	South Asian	1.0 (0.6 to 1.6)
	Black African	1.3 (0.8 to 2.0)
	Black Caribbean	3.0 (1.2 to 7.7)
	Other	1.9 (1.0 to 3.4)
	Previous tuberculosis	3.0 (1.9 to 4.9)
	Problem drug use ¹	-
	Imprisonment ²	3.0 (1.7 to 5.5)
	Hostel/street homeless ³	-
	Ever homeless ³	1.6 (1.1 to 2.2)
	Mental health problems	-
	<i>Risk factors for multidrug resistance in patients with tuberculosis</i>	
	<i>Risk factor</i>	<i>Adjusted OR (95% CI)</i>
	Age:	
	0-14 years	-
	15-29 years	-
	30-59 years	-
	≥60 years	-
	Male	-
	Born in the UK	-
	Ethnicity:	
	White	Reference
	South Asian	1.6 (0.8 to 3.0)
	Black African	2.5 (1.2 to 5.7)
	Black Caribbean	1.6 (0.3 to 10.2)
	Other	2.5 (0.9 to 7.1)
	Previous tuberculosis	7.8 (4.8 to 12.5)

Bibliographic reference	Story A, Murad S, Roberts W, Verheyen M, Hayward AC; London Tuberculosis Nurses Network (2007) Tuberculosis in London: the importance of homelessness, problem drug use and prison. Thorax 62(8): 667-71	
	Problem drug use ¹	-
	Imprisonment ²	-
	Hostel/street homeless ³	-
	Ever homeless ³	2.1 (1.1 to 4.1)
	Mental health problems	-
	<i>Risk factors for isoniazid resistance in patients with tuberculosis in a non-outbreak situation</i>	
	<i>Risk factor</i>	<i>Adjusted OR (95% CI)</i>
	Age:	
	0-14 years	0.8 (0.2 to 4.6)
	15-29 years	1.1 (0.7 to 1.7)
	30-59 years	Reference
	≥60 years	0.5 (0.3 to 1.2)
	Male	1.0 (0.7 to 1.6)
	Born in the UK	-
	Ethnicity:	
	White	Reference
	South Asian	1.0 (0.5 to 2.1)
	Black African	1.4 (0.7 to 2.6)
	Black Caribbean	1.6 (0.3 to 10.2)
	Other	2.5 (0.9 to 7.1)
	Previous tuberculosis	-
	Problem drug use ¹	-
	Imprisonment ²	-
	Hostel/street homeless ³	2.0 (0.9 to 4.5)
	Ever homeless ³	-
	Mental health problems	-
	<i>Risk factors for isoniazid resistance in patients with tuberculosis in an outbreak</i>	
	<i>Risk factor</i>	<i>Adjusted OR (95% CI)</i>
	Age:	

Bibliographic reference	Story A, Murad S, Roberts W, Verheyen M, Hayward AC; London Tuberculosis Nurses Network (2007) Tuberculosis in London: the importance of homelessness, problem drug use and prison. Thorax 62(8): 667-71		
	0-14 years		-
	15-29 years		-
	30-59 years		-
	≥60 years		-
	Male		-
	Born in the UK		2.8 (1.1 to 7.0)
	Ethnicity:		Reference
	White		1.1 (0.2 to 6.7)
	South Asian		0.8 (0.1 to 7.2)
	Black African		9.7 (2.6 to 35.4)
	Black Caribbean		6.1 (1.6 to 23.3)
	Other		-
	Previous tuberculosis		-
	Problem drug use ¹		3.5 (1.6 to 7.7)
	Imprisonment ²		10.3 (4.0 to 26.5)
	Hostel/street homeless ³		-
	Ever homeless ³		-
	Mental health problems		-
Source of funding	No details provided		
Comments			
	¹ Problem drug use was defined as injecting drug use or long duration/regular use of opiates, cocaine and/or amphetamines		
	² Imprisonment was defined as any period of incarceration during the current treatment episode		
	³ Homelessness was defined as living in direct access hostels or rough sleeping ever or during the current treatment episode		
	Abbreviations: CI, confidence interval; OR, odds ratio; RFLP, restriction fragment length polymorphism		

International surveillance data

High MDR-TB burden countries according to WHO 's Global TB Report 2014

	ESTIMATED % OF NEW TB CASES WITH MDR-TB ^a	CONFIDENCE INTERVAL	ESTIMATED % OF RETREATMENT TB CASES WITH MDR-TB ^b	CONFIDENCE INTERVAL
Armenia	9.4	7.0–12	43	38–49
Azerbaijan	13	10–16	28	22–34
Bangladesh	1.4	0.7–2.5	29	24–34
Belarus	35	33–37	55	51–57
Bulgaria	2.3	1.3–3.8	23	17–31
China	5.7	4.5–7.0	26	22–30
DR Congo	2.6	0.01–5.5	13	0.2–28
Estonia	17	12–24	48	32–63
Ethiopia	1.6	0.9–2.8	12	5.6–21
Georgia	11.0	9.7–13	38	34–42
India	2.2	1.9–2.6	15	11–19
Indonesia	1.9	1.4–2.5	12	8.1–17
Kazakhstan	25	24–26	55	54–56
Kyrgyzstan	26	23–31	55	52–58
Latvia	8.8	6.6–12	26	18–35
Lithuania	11	9.5–14	44	39–49
Myanmar	5.0	3.1–6.8	27	15–39
Nigeria	2.9	2.1–4.0	14	10–19
Pakistan	4.3	2.8–5.7	19	14–25
Philippines	2.0	1.4–2.7	21	16–29
Republic of Moldova	24	21–26	62	59–65
Russian Federation	19	14–25	49	40–59
South Africa	1.8	1.4–2.3	6.7	5.4–8.2
Tajikistan	13	9.8–16	56	52–60
Ukraine	14	14–15	32	31–33

